Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05928-7 ↗At a glance
Multizentrische Studie in Journal of Cancer Research and Clinical Oncology, 2024. Written by Axel Hegele and 12 co-authors. Institution: Urological Center Mittelhessen, DRK Hospital Biedenkopf, Biedenkopf, Germany. lexaelegeh@aol.com. Major MEDLINE topics: Thiohydantoins, Prostatic Neoplasms, Castration-Resistant. Cited 5 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: Philipps-Universität Marburg.
Abstract (original language)
Purpose
Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nevertheless real-world data are limited. The aim of this multicenter study was to generate real-world data from nmCRPC patients treated with ADT plus apalutamide.
Methods
In this observational cohort based investigator initiated trial data of nmCRPC patients receiving apalutamide plus ADT were collected focusing on patient demographic data, prostate-specific antigen (PSA) declines, safety profile including dose modification/discontinuation as well as subsequent therapy and metastasis-free survival (MFS).
Results
Data from a total of 31 nmCRPC patients were documented. Compared to the Phase III study Spartan real-world patients are older, showed a higher ECOG-PS and more aggressive tumors. In the cohort PSA decreased about 98.1%, 74% of patients showed a PSA decrease over 90% and 54.8% reached a PSA-level < 0.2ng/ml. Apalutamide was well tolerated in real world patients: adverse events occurred in 67.7% but were in the majority mild (≥ grade 3: 6.5%). Dose reduction was necessary in 38.7% and 32.2% discontinued apalutamide treatment. MFS was 43 months and majority of patients were subsequently treated with abiraterone.
Conclusion
In real world more comorbid nmCRPC patients with a higher ECOG-PS and more aggressive tumors are treated with apalutamide plus ADT. Nevertheless efficacy results as well as side effects are similar in real-world compared to Spartan trial showing also a rapid, durable and deep PSA response with a median MFS of 43 months.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Urological Center Mittelhessen, DRK Hospital Biedenkopf, Biedenkopf, Germany. lexaelegeh@aol.com.
- Department of Urology, Philipps University Marburg, Marburg, Germany. lexaelegeh@aol.com.
- Urological Center Mittelhessen, DRK Hospital Biedenkopf, Biedenkopf, Germany.
- Department of Urology, Philipps University Marburg, Marburg, Germany.
- Urologen am Ludwigsplatz, Giessen, Germany.
- Urological Center Wetterau, Büdingen, Germany.
Funding
- Philipps-Universität Marburg
Cite
APA
Hegele, A., Häußermann, R., Schultheis, S., Skrobek, L., Vink, M., Hollwegs, S., Ludwig, M., Huwe, P., Maywurm, M., Bartsch-Polle, A., Weber, J., Thiemer, M., & Varughese, D. (2024). Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05928-7
Vancouver
Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, et al. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05928-7
BibTeX
@article{Hegele2024,
author = {Hegele, Axel and Häußermann, Rainer and Schultheis, Stefan and Skrobek, Lennart and Vink, Meike and Hollwegs, Sebastian and Ludwig, Martin and Huwe, Petra and Maywurm, Manfred and Bartsch-Polle, Anke and Weber, Jost and Thiemer, Markus and Varughese, Denny},
title = {Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05928-7}
}
EUVIMED